MedTrace Logo

Feasibility of a Multi-omics Platform for Hematological Malignancies

NCT07445438 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1040

Last updated 2026-03-03

No results posted yet for this study

Summary

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.

Conditions

  • Myeloma Multiple
  • Chronic Leukemia
  • Acute Leukemia
  • Myeloproliferative Disorders
  • Lymphoproliferative Disorders
  • Myelodysplastic Disorders

Interventions

OTHER

Multi-omics analyses

The focus of our scientific approach is based on multi-omics analyses: NGS (Next Generation Sequencing analysis), Bulk Transcriptomics, Single-cell resolution, Single-cell transcriptomics and phosphoproteomics.

BIOLOGICAL

Functional tests

Functional analyses will be performed on primary sample from each enrolled patient. Malignant cells are cultered and incubated with a specific library of drugs (300 drugs) at four different concentrations for 72 hours.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria di Parma

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2030-03-31
Completion
2030-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07445438 on ClinicalTrials.gov